Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study

Inclusion Criteria: * Patient has descending thoracic aortic aneurysm (DTA) or type B aortic dissection (TBAD), who needs endovascular repair (TEVAR). * Life expectancy \> 1 year. * Patient or legally authorized representative understands the nature of the clinical trial, agrees to its provisions, agrees to comply with the requirements of the study including a 3-year follow-up, and signed applicable Informed Consent Form. * Patient's characteristics consistent with Ankura™ Stent Graft System IFU and sizing guidelines, which indicate as following: 1. For descending thoracic aortic aneurysm (DTA) patient: * Adequate iliac/femoral access vessel that is compatible with the required delivery system. * Aortic inner diameter in the range of 18-42mm. * ≥15mm non-aneurysmal aorta proximal and distal to the lesion. * Morphology suitable for endovascular repair. 2. For type B aortic dissection (TBAD) patient: * Adequate iliac/femoral access vessel that is compatible with the required delivery system. * ≥15mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected. Diameter at proximal extent of proximal landing zone in the range of 16-44mm. * ≥15mm landing zone distal to the primary entry tear; distal extent of the landing zone must not be dissected. Diameter at distal extent of distal landing zone in the range of 16-44mm. * Morphology suitable for endovascular repair. Exclusion Criteria: * Patient with any contraindications mentioned in the Ankura™ Stent Graft System IFU: * Patients with acute systemic infection; * Patients who have had other devices implanted in the cardiovascular cavity, which will interfere with the placement of this device; * Patients with mesenteric blood flow mainly supplied by the inferior mesenteric artery; * Patients who have allergic reaction to the device; * Patients who are not suitable for endovascular repair in vascular morphology; * Patients who cannot tolerate contrast agents due to severe renal insufficiency; * Patients who are allergic to contrast agents; * Aneurysms neck with thrombus; * Non-aneurysmal aortic proximal neck length \<1.5cm; * Non-aneurysmal aortic distal anchorage zone \<1.5cm; * For aneurysms, Non-aneurysmal aortic diameter \<18mm or \>42mm. For Type B dissections, Non-aneurysmal aortic diameter \<16mm or \>44mm. * Patient with traumatic aortic injury; * Patient with uncorrectable coagulopathy; * Patient with hereditary connective tissue disease, including but not limited to Marfan Syndrome or Ehlers-Danlos Syndrome; * Patient with morbid obesity, weight greater than 350 Pounds (150kg), or who cannot undergo accurate fluoroscopy examination due to obesity; * Age\<18 Years or Age\> 85 Years; * Pregnant or plan to be pregnant or breast feeding; * Myocardial infarction or stroke within 3 months prior to the procedure; * American Society of Anesthesiologists Physical Status Classification (ASA) classification 5 or higher; * Patient with an unstable angina pectoris or hearth insufficiency New York Heart Association Functional Classification (NYHA) 3 or 4 * Participant in other drug or medical device clinical trials; * Patient with access vessel which are to tortuous, narrow or any kind of reasons that would lead to failure of introduction and advancing an introducer sheath; * Any condition (medical or anatomic) which makes the patient not suitable for endovascular repair according to the opinion of the investigator.